secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001104659-25-106669
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics appoints Kathryn Penkus Corzo to Board; CEO granted 250,000 options
--------------------------------------------------------------------------------

- Kathryn Penkus Corzo appointed to Board effective Nov 1, 2025; she brings 30+ years of biopharma leadership.
- Corzo currently President/COO of bit.bio; previously Head of Oncology Cell Therapy at Takeda Ventures.
- Corzo received 147,611 stock options as non-employee director compensation, vesting over 36 months.
- CEO Juan Vera granted 250,000 stock options, vesting annually over 4 years under the 2020 Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925106669/0001104659-25-106669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925106669/tm2530129d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-106669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer